| 9th Apr 2026 7:00 am |
RNS |
Q1 2026 Business Update |
| 8th Apr 2026 7:00 am |
RNS-R |
Avacta Announces Science Day 2026 |
| 31st Mar 2026 7:00 am |
RNS |
First patient treated in Phase 1 trial of AVA6103 |
| 27th Mar 2026 7:00 am |
RNS |
Result of Oversubscribed Fundraise |
| 26th Mar 2026 5:16 pm |
RNS |
Proposed Fundraise to raise approximately £10m |
| 26th Mar 2026 4:44 pm |
RNS |
Issue of Equity |
| 17th Mar 2026 7:00 am |
RNS-R |
Presentations of pre|CISION® Platform Candidates |
| 17th Mar 2026 7:00 am |
RNS-R |
Presentations of pre|CISION® Platform Candidates |
| 16th Mar 2026 7:00 am |
RNS |
Phase 1 study opening for AVA6103 |
| 16th Mar 2026 7:00 am |
RNS |
Phase 1 study opening for AVA6103 |
| 24th Feb 2026 7:00 am |
RNS |
PreCISION payload delivery advantage over ADC |
| 18th Feb 2026 7:00 am |
RNS-R |
Avacta to Participate in Conference March 2026 |
| 9th Feb 2026 7:00 am |
RNS |
Appointment of CSO |
| 3rd Feb 2026 7:00 am |
RNS |
Faridoxorubicin Program Clinical Updates |
| 21st Jan 2026 7:00 am |
RNS |
FDA Clearance of IND Application for AVA6103 |
| 20th Jan 2026 7:01 am |
RNS |
Year-end trading update |
| 20th Jan 2026 7:00 am |
RNS |
Appointment of Nominated Adviser & TVR |
| 18th Dec 2025 7:00 am |
RNS-R |
Avacta reports new AVA6103 pharmacology data |
| 17th Dec 2025 7:00 am |
RNS |
Faridoxorubicin Phase 1b SGC data |
| 8th Dec 2025 7:00 am |
RNS |
Preliminary Data in Faridoxorubicin Phase 1b Trial |
| 3rd Nov 2025 8:24 am |
RNS |
Completion of Placing and TVR |
| 27th Oct 2025 5:39 pm |
RNS |
Block Listing Six Monthly Return |
| 27th Oct 2025 7:00 am |
RNS |
Avacta presents preclinical data at AACR-NCI-EORTC |
| 23rd Oct 2025 5:00 pm |
RNS-R |
Notice of Investor Presentation |
| 20th Oct 2025 7:01 am |
RNS |
Equity fundraise of £16 million |
| 20th Oct 2025 7:00 am |
RNS |
Avacta Presents Phase 1a Data for Faridoxorubicin |
| 13th Oct 2025 7:00 am |
RNS |
Avacta to present data at EORTC-NCI-AACR |
| 30th Sep 2025 7:00 am |
RNS |
Interim Half Year Results 2025 |
| 15th Sep 2025 7:00 am |
RNS |
Notice of Interim Results |
| 9th Sep 2025 7:00 am |
RNS-R |
Shortlisted for AIM Awards Technology of the Year |
| 1st Sep 2025 7:00 am |
RNS |
Avacta completes sale of Coris Bioconcept |
| 29th Aug 2025 7:00 am |
RNS |
Amendments to Convertible Bond + equity fundraise |
| 30th Jul 2025 7:00 am |
RNS |
Avacta to Present at ESMO Congress |
| 28th Jul 2025 7:48 am |
RNS |
Agreement to Sell Coris Bioconcept SRL |
| 21st Jul 2025 7:00 am |
RNS |
Payment of Convertible Bond Installment |
| 17th Jul 2025 7:00 am |
RNS |
Equity fundraise of £3.25 million |
| 2nd Jul 2025 5:00 pm |
RNS |
Result of AGM |
| 2nd Jul 2025 7:00 am |
RNS |
Q2 2025 Business Update |
| 1st Jul 2025 7:00 am |
RNS |
Management Team Appointments |
| 30th Jun 2025 3:00 pm |
RNS |
Appointment of Zeus Capital as Joint Broker |
